Synthetic Human Secretin in Children With Autism

NCT ID: NCT00036244

Last Updated: 2005-08-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2002-04-30

Study Completion Date

2004-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RG1068 (Synthetic Human Secretin)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Autism
Minimum Eligible Age

32 Months

Maximum Eligible Age

59 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Repligen Corporation

INDUSTRY

Sponsor Role lead

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southwest Autism Research Center

Phoenix, Arizona, United States

Site Status

UCLA Pediatric Neurology

Los Angeles, California, United States

Site Status

Children's Hospital and Research Center at Oakland

Oakland, California, United States

Site Status

1st Allergy & Clinical Research Center

Centennial, Colorado, United States

Site Status

Alachua Family Psychiatry

Gainesville, Florida, United States

Site Status

Miami Children's Hospital

Miami, Florida, United States

Site Status

Riley Children's Hospital

Indianapolis, Indiana, United States

Site Status

The Clinical Trials Center:A Division of Children's Hospital

Metairie, Louisiana, United States

Site Status

Hardy Healthcare Associates

Hingham, Massachusetts, United States

Site Status

Children's Hospital of Michigan

Detroit, Michigan, United States

Site Status

University of Medicine and Dentistry of New Jersey

Newark, New Jersey, United States

Site Status

Schneider Children's Hospital

New Hyde Park, New York, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

Children's Biomedical Center of Utah

Sandy City, Utah, United States

Site Status

Puget Sound Neurology

Edmonds, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RG1068-04

Identifier Type: -

Identifier Source: org_study_id